Table 1:
A single type of TCR prevents tumor development if cognate antigen is expressed by all cancer cells, whereas TCR diversity, as determined in Figure 1D, is required to eliminate cancers displaying antigenic heterogeneity.
| Group | Specificity of transgenic TCR |
TCRtg T cells in repertoire |
Tumor growth after cancer cell inoculation* | ||||
|---|---|---|---|---|---|---|---|
| MC57 | MC57- SIY |
MC57- mp68 |
8101- bulk |
8101- clone |
|||
| Rag+/− | – | – | 0/6 | 0/5 | 0/8 | 0/8 | 0/5 |
| 2CxRag+/− | Anti-SIY | ~95% | 5/5a | 0/8 | 5/5c | 10/13d | ND |
| 2CxRag−/− | Anti-SIY | 100% | 5/5 a | 0/5 | 4/4#,a | 5/5 | ND |
| Rag−/− | – | – | 5/5 a | 5/5b | 5/5c | 5/5 | 5/5b |
| 1D9xRag−/− | Anti-mp68 | 100% | 5/5 a | 5/5 b | 0/8 | 7/7§ | 0/15¶ |
2-6-month-old mice were inoculated subcutaneously with the indicated cancer cells. Mice listed as tumor-free had no visible tumor at the injection site 3 weeks after subcutaneous inoculation. Experiments pooled from 2-3 independent experiments.
Tumor-free mice were kept for 100 days after inoculation to monitor for relapse.
An additional mouse was found dead 9 days after injection before a tumor developed.
Data detailed in Figure 2.
An additional mouse developed a tumor but was excluded because it also developed leukemia. The resected tumor was still recognized by 1D9 T cells.
p=0.001 vs. Rag+/−.
p=0.008 vs. Rag+/−.
p=0.001 vs. Rag+/−.
p=0.001 vs. Rag+/−. TCRtg: TCR-transgenic; ND: not done.